Warning! GuruFocus detected
1 Severe warning sign
with VERV.
Try a 7-Day Free Trial
to check it out.
What is a stock summary page? Click here for an overview.
Business Description
Verve Therapeutics Inc
NAICS : 541714
SIC : 2833
ISIN : US92539P1012
Description
Verve Therapeutics Inc clinical-stage company developing a new class of genetic medicines for cardiovascular disease, or CVD, with the potential to transform treatment from chronic therapies to single-course gene editing medicines. The current paradigm of chronic care is fragile requiring rigorous patient adherence, extensive healthcare infrastructure, and regular healthcare access, and leaves many patients without adequate care. Its pipelines are PCSK9, ANGPTL3, and LPA. The group has one reportable segment relating to the research and development of gene-editing medicines. The segment derives its current revenues from research and development collaborations.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 7.49 | |||||
| Equity-to-Asset | 0.76 | |||||
| Debt-to-Equity | 0.14 | |||||
| Debt-to-EBITDA | -0.32 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 0.16 | |||||
| Beneish M-Score | -1.82 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 6.3 | |||||
| 3-Year EPS without NRI Growth Rate | 19.4 | |||||
| 3-Year FCF Growth Rate | 14.6 | |||||
| 3-Year Book Growth Rate | -9 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | -27.48 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 25.84 | |||||
| 9-Day RSI | 31.77 | |||||
| 14-Day RSI | 35.67 | |||||
| 3-1 Month Momentum % | 5.15 | |||||
| 6-1 Month Momentum % | 27.11 | |||||
| 12-1 Month Momentum % | -52.33 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 12.65 | |||||
| Quick Ratio | 12.65 | |||||
| Cash Ratio | 12.22 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -22.3 | |||||
| Shareholder Yield % | -8.88 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -707.23 | |||||
| Net Margin % | -614.59 | |||||
| FCF Margin % | -499.28 | |||||
| ROE % | -36.39 | |||||
| ROA % | -28.41 | |||||
| ROIC % | -171.39 | |||||
| 3-Year ROIIC % | -131.5 | |||||
| ROC (Joel Greenblatt) % | -223.93 | |||||
| ROCE % | -34.61 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 13.88 | |||||
| PB Ratio | 0.94 | |||||
| Price-to-Tangible-Book | 0.94 | |||||
| EV-to-EBIT | -0.04 | |||||
| EV-to-Forward-EBIT | -2.92 | |||||
| EV-to-EBITDA | -0.04 | |||||
| EV-to-Forward-EBITDA | -3 | |||||
| EV-to-Revenue | 0.29 | |||||
| EV-to-Forward-Revenue | 0.26 | |||||
| EV-to-FCF | -0.06 | |||||
| Price-to-Net-Current-Asset-Value | 1.19 | |||||
| Price-to-Net-Cash | 1.25 | |||||
| Earnings Yield (Greenblatt) % | -2500 | |||||
| FCF Yield % | -34.83 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:VERV
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Verve Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 32.332 | ||
| EPS (TTM) ($) | -2.35 | ||
| Beta | 1.66 | ||
| 3-Year Sharpe Ratio | -0.13 | ||
| 3-Year Sortino Ratio | -0.21 | ||
| Volatility % | 93.54 | ||
| 14-Day RSI | 35.67 | ||
| 14-Day ATR ($) | 0.510655 | ||
| 20-Day SMA ($) | 5.97 | ||
| 12-1 Month Momentum % | -52.33 | ||
| 52-Week Range ($) | 4.305 - 13.24 | ||
| Shares Outstanding (Mil) | 88.8 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Verve Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Verve Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Verve Therapeutics Inc Frequently Asked Questions
What is Verve Therapeutics Inc(VERV)'s stock price today?
The current price of VERV is $5.22. The 52 week high of VERV is $13.24 and 52 week low is $4.31.
When is next earnings date of Verve Therapeutics Inc(VERV)?
The next earnings date of Verve Therapeutics Inc(VERV) is 2025-05-15 Est..
Does Verve Therapeutics Inc(VERV) pay dividends? If so, how much?
Verve Therapeutics Inc(VERV) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers